EMERYVILLE, Calif., Feb. 7, 2012 (GLOBE NEWSWIRE) — NovaBay Pharmaceuticals, Inc. (NYSE Amex:NBY), a clinical stage biotechnology company developing its first-in-class, anti-infective Aganocide (R) compounds for the topical treatment and …
NovaBay Pharmaceuticals to Hold Conference Call to Provide Year-End Business Update and 2012 Outlook – Yahoo Finance